Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF-POLARIS
2025-523717-29-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Modality
- Small Molecules, Peptides
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF), heart failure with mid-range ejection fraction (HFmrEF) and obesity comparing Zenagamtide with Placebo (2 arms). Primary endpoint: Time to first occurrence of a composite heart failure endpoint. Planned start Apr 2026; status: authorised.
02
Drugs
amycretin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)obesity
Beyond the preview
Go deeper on 2025-523717-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523717-29-00.